A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 680 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Η ΚΑΘΗΜΕΡΙΝΟΤΗΤΑ December 10, 2018 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... February 24, 2026 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer...
